Compare Enveric Biosciences Inc (ENVB) vs Public Service Enterprise Group Incorporated Common Stock (PEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Public Service Enterprise Group Incorporated Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.2 (market cap $6.27M), while Public Service Enterprise Group Incorporated Common Stock trades at $69.9 (market cap $35.12B). The key difference: Public Service Enterprise Group Incorporated Common Stock is far larger — about 5601.3× Enveric Biosciences Inc's market cap, and Public Service Enterprise Group Incorporated Common Stock pays a 3.8% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Public Service Enterprise Group Incorporated Common Stock for 0 Days on average.
| ENVB | PEG | |
|---|---|---|
Market Cap | $6.27M | $35.12B |
Volume | 100,675 | 4,400,164 |
Sector | Health | Utilities |
52-Week High | $10.80 | $86.95 |
52-Week Low | $1.27 | $66.56 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.03M | $59.61B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and no revenue in 2025, though it has consistently beaten EPS estimates. Recent news highlights patent approvals and positive preclinical data for its neuroplastogenic therapeutics.
The outlook remains speculative given the lack of revenue and negative cash flow from operations. Analyst consensus is 75% buy, but high business execution risks and dependence on drug development success pose significant challenges for near-term shareholder value.
Public Service Enterprise Group (PEG) trades at $70.47, down 0.41% on the day, showing neutral technical signals with support at $70 and resistance at $71. The company maintains solid fundamentals with a 17.53 P/E ratio and consistent earnings beats in recent quarters, though Q3 2026 results are pending. Revenue grew to $12.17B in 2025 with a healthy 16.04% net income margin, while analyst consensus remains mixed with a $83.40 price target suggesting potential upside.
PEG presents a stable utility investment with regulated growth and nuclear assets supporting a 6-8% earnings outlook. Key risks include regulatory approvals for capex plans and interest rate sensitivity. Institutional buying and a 15-year dividend growth streak add appeal, but recent CEO stock sales and proximity to 52-week lows warrant caution amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Public Service Enterprise Group Incorporated Common Stock
Public Service Enterprise Group Incorporated is a New Jersey-based utility holding company operating through Public Service Electric and Gas Co. (PSE&G), which transmits and distributes electricity and distributes natural gas, and PSEG Power, which operates the Salem and Hope Creek nuclear generating stations. It also runs the Long Island Power Authority's electric system under contract via PSEG Long Island.
Read more on PEG →
